Special imaging primarily means advanced MRI techniques used for qualitative and quantitative measurement of biological metabolism as e.g., spectroscopy, perfusion imaging (PWI, ASL), diffusion weighted imaging (DWI, DTI, DTT) and brain function (BOLD, fMRI). This physiological magnetic resonance techniques offer insights into brain structure, function, and metabolism.
Spectroscopy provides functional information related to identification and quantification of e.g. brain metabolites. MR perfusion imaging has applications in stroke, trauma, and brain neoplasm. MRI provides the high spatial and temporal resolution needed to measure blood flow to the brain. arterial spin labeling techniques utilize the intrinsic protons of blood and brain tissue, labeled by special preparation pulses, rather than exogenous tracers injected into the blood.
MR diffusion tensor imaging characterizes the ability of water to spread across the brain in different directions. Diffusion parallel to nerve fibers has been shown to be greater than diffusion in the perpendicular direction. This provides a tool to study in vivo fiber connectivity in brain MRI.
FMRI allows the detection of a functional activation in the brain because cortical activity is intimately related to local metabolism changes.

See also Diffusion Tensor Tractography.

From Toshiba America Medical Systems Inc.;
With its high-field strength, the Vantageâ„¢ delivers the clinical capabilities and image quality expected by cardiologists, while simultaneously offering patients a more comfortable and non-invasive option, said Dane Peshe, director, MRI Business Unit, Toshiba America Medical Systems. Vantageâ„¢ supports a full complement of cardiovascular imaging studies, ranging from stroke evaluation to peripheral vascular imaging. Additionally, the ultra short bore design offers patients a greater feeling of openness that reduces claustrophobic sensations, while Toshiba's exclusive, patented Pianissimoâ„¢ technology reduces scan noise by as much as 90 percent for a more pleasant experience.'

From Hitachi Medical Systems America, Inc.;
the AIRIS made its debut in 1995. Hitachi followed up with the AIRIS II system, which has proven equally successfully. 'All told, Hitachi has installed more than 1,000 MRI systems in the U.S., holding more than 17 percent of the total U.S. MRI installed base, and more than half of the installed base of open MR systems,' says Antonio Garcia, Frost and Sullivan industry research analyst. Now Altaire employs a blend of innovative Hitachi features called VOSIâ„¢ technology, optimizing each sub-system's performance in concert with the other sub-systems, to give the seamless mix of high-field performance and the patient comfort, especially for claustrophobic patients, of open MR systems.

From Aurora Imaging Technology, Inc.;
The Aurora® 1.5T Dedicated Breast MRI System with Bilateral SpiralRODEO™ is the first and only FDA approved MRI device designed specifically for breast imaging. The Aurora System, which is already in clinical use at a growing number of leading breast care centers in the US, Europe, got in December 2006 also the approval from the State Food and Drug Administration of the People's Republic of China (SFDA).
'Some of the proprietary and distinguishing features of the Aurora System include: 1) an ellipsoid magnetic shim that provides coverage of both breasts, the chest wall and bilateral axillary lymph nodes; 2) a precision gradient coil with the high linearity required for high resolution spiral reconstruction;; 3) a patient-handling table that provides patient comfort and procedural utility; 4) a fully integrated Interventional System for MRI guided biopsy and localization; and 5) the user-friendly AuroraCADâ„¢ computer-aided image display system designed to improve the accuracy and efficiency of diagnostic interpretations.'

[This entry is marked for removal.]

Cytogen Corporation of Princeton, NJ is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets several products through its in- house oncology sales force: ProstaScint® (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed™ I-125 and BrachySeed™ Pd-103 (two uniquely designed, next generation radioactive seed implants for the treatment of localized prostate cancer), and NMP22® BladderChek™ (a highly accurate and convenient antibody-based point-of-care staging test for bladder cancer detection). Cytogen has also developed Quadramet®, a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer. Cytogen's pipeline comprises product candidates at various stages of clinical development, including fully human monoclonal antibodies and cancer vaccines based on PSMA (prostate specific membrane antigen) technology, which was exclusively licensed from Memorial Sloan-Kettering Cancer Center.
A license and marketing agreement with AMAG Pharmaceuticals Inc' (formerly Advanced Magnetics), to market the functional molecular imaging agent Combidex®, was terminated in 2007.